Credit: Getty Images. Brexpiprazole is an atypical antipsychotic. The Food and Drug Administration (FDA) has approved Rexulti ® (brexpiprazole) for the treatment of agitation associated with dementia ...

The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.

Brexpiprazole is an atypical antipsychotic indicated for use as adjunctive therapy to antidepressants for the treatment of major depressive disorder and schizophrenia. Zydus Cadila has received a ...

Following a negative FDA advisory committee vote earlier this year, the other shoe has dropped for Lundbeck and Otsuka Pharmaceutical’s post-traumatic stress disorder (PTSD) hopeful. The FDA has ...